SPATA13

Across TCGA pan-cancer cohorts, SPATA13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA13 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SPATA13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA13 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where SPATA13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.826	0.664	.003	9	view →
LUAD	DFS	Median	II,III,IV	1.000	0.718	.024	5	view →
LSCC	DFS	Median	II,III,IV	1.000	0.482	.026	1	view →
CCRCC	DFS	Tertile	II,III,IV	0.482	0.832	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA13–GBM (DFS)

Open the GBM breakdown →